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INTRODUCTION
Human cytomegalovirus (CMV) is a ubiquitous her-
p e s v i rus and a common cause of opportunistic infections,
often as a result of reactivation of latent virus that follows
f rom decreased immunosurveillance [1]. The widespre a d
distribution of latent virus in the general population has
made the occurrence of CMV disease following blood and
m a rrow allograft transplantation particularly significant,
even with the available antiviral therapy [2]. Although
latency remains poorly understood, and sites of latent virus
residence have not been fully characterized, reactivation of
latent virus remains the single most important determinant
of CMV disease following transplantation or immunosup-
p ression. Bone marrow–derived granulocyte-macro p h a g e
p rogenitors that give rise to peripheral blood monocytes
and tissue macrophages have been implicated as import a n t
reservoirs of latent virus [3-9]. Although the CMV genome
is highly complex and contains over 200 putative genes
[9,10,11], viral gene expression is highly restricted during
latency [9,10,12]. Two types of transcripts—denoted sense
and antisense CMV latency-associated transcripts—specifi-
cally detected in latently infected granulocyte-macro p h a g e
p rogenitors have been mapped to the i e1 /i e2 region of the
CMV genome [8] (Figure 1). Sense transcripts have been
more frequently detected than antisense transcripts in bone
m a rrow–derived mononuclear cells from naturally infected
individuals [8]. Sense t ranscr ipt s  are  de tected  in a
smal l percentage of C D 3 3+ p rogenitors of monocytes,
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ABSTRACT
Latent human cytomegalovirus (CMV) infection of hematopoietic progenitor cells is associated with the pre s-
ence of latency-associated transcripts that may express 6 proteins larger than 44 amino acids in size (open
reading frame [ORF] 55, ORF45, ORF94, ORF59, ORF154, ORF152/UL124). The serologic response to
these proteins was evaluated in healthy seropositive individuals as well as in individuals undergoing active
CMV infection. Individual recombinant GST-fusion proteins, pre p a red from bacteria, were found by enzyme-
linked immunosorbent assay to be recognized by between 8% and 44% long-term healthy seropositive indi-
viduals, with ORF94 and ORF55 being the most broadly and significantly recognized. Although nearly all of
s e rum samples (85%) recognized at least 1 of these proteins, none reacted with all 6. Patterns of antibody
p revalence to these proteins in long-term seropositive individuals were similar to many antigens expre s s e d
during productive replication (IE1, ppUL57, ppUL83/pp65), but none were broadly detected by a majority of
individuals, a characteristic of only a few productive-phase antigens, including ppUL44/ICP36 and
ppUL32/pp150. Consistent with prevalence in long-term seropositive individuals, commercial preparations of
pooled human gamma globulin were also found to recognize latency-associated proteins. Serologic re a c t i v i t y
to latency-associated proteins was slow to develop following primary infection, in a pattern distinct from any
of the characterized replication-phase proteins tested here, and was boosted late after secondary infection or
reactivation in solid-organ transplant recipients without showing a correlation with viremia or disease. These
results provide evidence that proteins expressed from the latent region during natural infection exhibit
immunogenicity comparable with most other characterized viral antigens, although the narrow response to
individual latency-associated proteins likely precludes their use in serologic assays to investigate clinical cor-
relates or outcome in transplant re c i p i e n t s .
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granulocytes, and m o n ocyte-derived dendritic cells, but are
not detectable in T-cells, B-cells, mature monocytes, or
m a t u re granulocytes from naturally infected bone marro w
donors [10,12]. 
Both types of latency-associated transcripts contain
open reading frames (ORFs) that are associated with the
latent phase (LP) of infection [7,8]. These ORFs are not
contained on any known productive phase (PP) transcript.
Sense latent transcripts carry 3 ORFs (ORF55, ORF45, and
ORF94) and antisense transcripts carry 3 ORFs (ORF59,
ORF154, and ORF152, which is also designated UL124)
l a rger than 44 codons that are conserved among CMV
strains (Figure 1). Although LP transcripts have been
detected in hematopoietic progenitors from healthy
seropositive carriers, the only evidence suggesting that they
encode proteins has been derived from serologic analyses.
Consistent with the expression of transcripts, antibodies
specific for ORF94 and ORF152 have been detected in sera
by immunoblot from 7 and 3, re s p e c t i v e l y, of 15 fro m
healthy CMV-seropositive individuals [8].
P roductive CMV infection elicits a strong humoral
immune response to both structural and nonstructural viral
p roteins. A detailed analysis of this response in diff e re n t
clinical settings has been the subject of considerable work
over the past 15 years [13]. Certain PP proteins are highly
immunogenic, a characteristic that has led to the use of
recombinant protein-based assays to monitor sero c o n v e r-
sion during secondary infection and longevity of sero l o g i c
responses in healthy carriers [14-18]. When assayed individ-
u a l l y, the immunogenicity of PP proteins can be divided
into 4 categories: (1) proteins that represent most viral anti-
gens such as IE1 (ppUL123) and ppUL54 (DNA poly-
merase) induce a weak response in a small percentage of
s e ropositive individuals or a response of short duration
[17,18]; (2) proteins such as ppUL83 (pp65) induce a strong
but short-lived antibody response (Landini, unpublished
data); (3) proteins such as pUL80a (virion-assembly protein)
or ppUL57 (single-stranded DNA binding protein) induce
an IgM-specific response [15,19,20], and ppUL90 (pp28)
[21] induces an IgG-specific response; (4) proteins such as
ppUL32 (pp150) elicit a strong and last ing re s p o n s e
detectable years after resolution of acute infection [14,22],
or proteins such as ppUL44 (p52, ICP36) that elicit a strong
early and lasting response in a majority of individuals fol-
lowing active infection. Because of a broad pattern of recog-
nition, ppUL32 and ppUL44 have been used as surro g a t e
markers to follow the serologic response to CMV [15,23,24].
These proteins contain linear epitopes that are highly
immunogenic in many animal species.
Although both the existence and character of the
humoral immune response to PP proteins is well estab-
lished, nothing is known about the characteristics of the
immune response against predicted LP proteins. The pur-
pose of this study was to determine whether antibodies to
p redicted LP gene products appeared in sera and whether
the patterns of response to these antigens would pro v i d e
Figure 1. Genomic map position of the ORFs for LP and PP proteins used in this study. The top line shows the CMV genome with PP ORFs UL32, UL44,
UL57, UL83, UL80a, IE2/UL122 and IE1/UL123 indicated [10]. The expanded segment shows a schematic of ie1/ie2 region transcripts detected in this region
during the productive phase, with IE1/UL123 indicated, and latent phase [9], with ORF94, ORF45, ORF55 indicated on sense transcripts and ORF 59,
ORF154, and ORF152/UL124 indicated on antisense transcripts.
102
i n f o rmation about the virus–host interaction. The re s u l t s
suggest that 85% of long-term seropositive individuals rec-
ognize 1 or more of the LP proteins, but that the percent-
age of individuals responding to any 1 of these proteins is
relatively low, an overall pattern similar to category 1 PP
p roteins. Consistent with the relative weakness of the
response, the serologic response to LP proteins following
active CMV infection is delayed relative to PP proteins.
MATERIALS AND METHODS
Construction of Plasmids and Fusion Pr o t e i n s
Plasmids pON2501, pON2303 (GST- O R F 9 41 - 9 4) ,
pON2304 (GST- O R F 1 5 46 - 1 2 0), pON2305 (GST- O R F 1 5 21 -
1 5 2), and pON2307 (GST- I E 12 3 2 - 4 0 0) have been described
previously [9]. Plasmid pEQ593 (GST-ORF551-55) was pre-
p a red by amplifying the 5′ end of the sense transcript by
polymerase chain re a c t i o n (PCR) using 5′- G T T T G G TA C
C G A G T C A C T C T T G G C A C G G G G A A - 3′ and 5′- G T T
TA A G C T T G T G TAT C ATAT G C C A A G T- 3′ as primers
and CMV (Towne) DNA as the template. This PCR prod-
uct was digested with HindIII and HincII, overhanging ends
w e re filled in using Klenow polymerase, and the re s u l t i n g
fragment was cloned into the SmaI site of pGEX1 to gener-
ate pEQ593. To construct GST-IE1132-274 (pON2990), a 429
bp E c oRV fragment from pON308G was cloned into the
S m aI site of pGEX-3X. To construct GST- O R F 4 52 - 4 5
(pON2991), a 380-bp HaeIII fragment from pON2501 was
cloned into S m aI site of pGEX-1N. To construct GST-
O R F 5 91 - 5 9 (pON2993), plasmid pON308G was amplified
with PCR with primer ORF59A (5′- C G G G AT C C G C G
AT G G C C C G TA G G T- 3′) and primer ORF59B (5 ′-
G T G A AT T C T G T C G G G T G C T G - 3′) and the PCR
p ro duct was cloned into pGEM-T (Promega) to make
pON2992. A 216 bp B a mH I /E c oRI fragment from pON2992
was then cloned between the B a mHI and E c oRI sites of
PGEX-2TK [25] to make pON2993. All clones were sub-
jected to nucleotide sequencing using pGEX-specific primer
5′-ATAGCATGGCCTTTGCAGGG-3′. Growth of bacte-
ria for preparation of fusion proteins was performed accord-
ing to the methods described by Kondo et al. [7]. The PP
CKS-fusion proteins used in this work were obtained as
described previously [26,27].
Purification of Fusion Proteins 
G S T-ORF55 and GST-ORF59 were pre p a red as
described previously [9]. GST-ORF45, GST-ORF94, GST-
ORF152, and GST-ORF154 were purified by electroelution
using standard protocols [26,27]. Briefly, after separation on
10% polyacrylamide preparative gels, proteins were stained
with CuCl2, the bands corresponding to fusion pro t e i n s
w e re cut out, placed into dialysis tubing (Spectra/Pore
membrane MW 6000-8000; Spectrum, Laguna Hills, CA),
and electroeluted for 5 hours at 120 V. Electro e l u t e d p ro-
teins were concentrated with a Centricon 30 (Amicon,
B e verly, MA) and protein concentration was determined by
Bio-Rad protein assay (Bio Rad, Richmond, CA).
Insoluble CKS-CMV fusion proteins (containing por-
tions of pUL32, ppUL44, ppUL83, ppUL57) were initially
purified after lysis by a combination of detergent washes fol-
lowed by being made soluble in 8 mol/L urea as previously
described [23]. After being made soluble in 8 mol/L ure a ,
the fusion proteins were purified by Sepharose Q chro-
matography (Pharmacia Biotech, Piscataway, NJ). Soluble
CKS-fusion protein ppUL80a was purified after cell lysis on
p reparative SDS-PAGE using a Bio-Rad Prep Cell (Bio-
Rad). Soluble control CKS protein was purified by DEAE
S e p h a d e x c h romatography after cell lysis and ammonium
sulfate precipitation.
Human Serum Samples 
The first group of sera were used to determine cutoff val-
ues and were obtained from 30 subjects who were randomly
chosen as blood donors and 16 healthy adults without
detectable CMV IgG by either  conventional enzyme
immunoassay or immunoblot assay. The second group of sera
was obtained from 36 subjects who were randomly chosen as
blood donors judged seropositive (IgG) for CMV by both
conventional enzyme immunoassay and immunoblot assay.
The third group of sera was obtained from 39 immunocom-
petent subjects (mainly pregnant women) who had underg o n e
recent active CMV infection and were judged sero p o s i t i v e
(IgM) for CMV by conventional enzyme immunoassay and
immunoblot assay. A fourth group of 185 serum samples was
obtained from 29 immunocompetent (21 pregnant women
and 8 young adults) and 13 immunocompromised individuals
(10 heart and 3 kidney transplant recipients) undergoing cul-
t u re - c o n f i rmed [28] or antigenemia-confirmed [29,30]
p r im a ry CMV infection. A fifth group of sera consisted of
149 samples from 7 immunocompetent adults (pre g n a n t
women) and 12 immunocompromised individuals (9 heart
and 3 kidney transplant recipients) undergoing culture - c o n-
firmed or antigenemia-confirmed secondary CMV infection.
P regnant women were examined at the clinic in Bologna
to confirm an active CMV infection. Two or 3 serum samples
w e re sequentially obtained from each of these women at
2- to 4-week intervals. Young adults with CMV infectious
mononucleosis were hospitalized, and serum was obtained 2
to 3 times at 2- to 4-week intervals. Transplant re c i p i e n t s
w e re virologically (urine cultures) and serologically moni-
t o red for CMV infection weekly during the first 2 months
after transplantation, at 2-week intervals during the third
month, at monthly intervals until the twelfth month, and then
p e r i o d i c a l l y.
CMV Ser o l o gy Assa y s
Conventional enzyme immunoassay and re c o m b i n a n t
p rotein enzyme immunoassay for anti-CMV IgG was per-
formed with a commercial kit (Enzygnost anti-HCMV/IgG
EIA alpha method, Behring AG, Marburg, Germ a n y ) .
Plates were read on a microEIA automatic reader (Behring
AG). Conventional and recombinant protein enzyme
immunoassay for anti-CMV IgM was perf o rmed using the
Enzygnost Anti-HCMV/IgM kit (Behring AG). Both kits
were used and the results were interpreted as suggested by
the manufacturers. For recombianant protein enzyme
immunoassay, 0.1 µg per well of purified recombinant pro-
tein in bicarbonate buffer (pH 9.6) was used to coat enzyme
immunoassay 96 well plates (A/S NUNC, Roskilde, Den-
mark). After an overnight incubation at 4oC, plates were
rinsed 3 times with phosphate-buff e red sodium ( P B S ) -Tween
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20 (sigma chemicals, St. Louis Missouri) (0.05%) and incu-
bated with bovine serum albumin, (BSA) (1%) in bicarbon-
ate buffer (pH 9.6). After 1 hour of incubation at room tem-
perature, wells were rinsed 3 times with PBS-0.05% Tween
20 and then incubated at 37oC for 2 hours with h u m a n
s e rum samples used at a dilution of 1:100 in PBS (50 µ L
final volume per well). After 3 washes with PBS-Tween 20,
p e roxidase-conjugated antihuman g or m chain antibodies
were added to wells, and plates were incubated at 37oC for
1.5 hours. After 3 washes with PBS-Tween 20, the presence
of antibody was detected by the addition of chro m o g e n
tetramethylene benzidine dihydrochloride (TMB). The
reaction was stopped after 1 hour by the addition of sulfuric
acid (0.5 N), and the results were read on the Micro E I A
re a d e r. For each sample, the immunoreaction level was
d e t e rmined as the diff e rence (recombinant antigen minus
the control fusion protein antigen) in readings at the
absorbance (OD4 5 0). The cutoff value for each fusion pro-
tein was set at a value higher than any value from 46 sera
that were CMV IgG-seronegative by either conventional
enzyme immunoassay or immunoblot analysis.
Six standard sera whose reactivity was pre v i o u s l y
assayed in 4 independent experiments were included to per-
f o rm linear re g ression analyses and to standardize each ru n .
Runs were considered acceptable when the values of the
i n t e rnal control sera were within an interval defined by
2 SD around the mean. Immunoblot assays were perf o m e d
by a recently developed modification [31] that allowed the
convenient addition of 3 recombinant CMV pro t e i n s
(ppUL32, ppUL44, and ppUL57), as well as a positive
(human g or m chains) and a negative (GST or CKS) con-
t rol to blots of CMV-infected cell extracts. Statistical evalu-
ation of data employed Statview 5.0.1 (SAS Institute, Cary,
NC) run on a Macintosh computer.
RESULTS
In order to investigate the presence of IgG antibody
d i rected against LP proteins in a large number of serum sam-
ples, 6 predicted latent gene products as well as 2 groups of
immunogenic PP proteins were evaluated in parallel by
recombinant protein enzyme immunoassay. The sero l o g i c
response to each of the 6 LP proteins (ORF55, ORF45, and
ORF94 from sense transcripts; ORF59, ORF154, and
ORF152 from antisense transcripts) were compared with
6 PP fusion proteins (nonstructural proteins IE1, ppUL44,
and ppUL57; structural proteins ppUL83, pUL80a, and
ppUL32) that had been the subject of previous detailed evalu-
ation [13,14,17,20,23,24,32]. The immune response to these
p roteins was investigated in 409 total serum samples derived
f rom both healthy individuals and patients in diff e rent clinical
settings. For comparison and to provide a range of examples,
the immunogenicity of the CMV PP proteins chosen for
comparison was known to vary and to re p resent a range of
possible response patterns. The nonstructural proteins chosen
for inclusion included IE1, which elicits a poor humoral
response [17,32]; ppUL44, which elicits a strong and lasting
response [23,24]; and ppUL57, which elicits mainly an IgM
response [20]. The structural proteins and protein fragments
chosen for comparison (ppUL83, pUL80a, and ppUL32)
include the most immunogenic antigens in the viral part i c l e
[13]. The fragment ppUL32, in part i c u l a r, is known to elicit
the strongest and longest lasting antibody response in a larg e
number of infected individuals [14,22].
I n i t i a l l y, 46 human sera that were CMV IgG-negative by
both conventional enzyme immunoassay and immunoblot
assay were used to determine background reactivity of each
fusion protein in an enzyme-linked immunosorbent assay
(ELISA). The background values for diff e rent pro t e i n s
ranged from 80 to just over 200 OD4 5 0 units. Overall, pre-
dicted LP proteins exhibited a significantly lower overall
b a c k g round reactivity than did PP proteins when compare d
by the Mann-Whitney test (P = <.0001). Initially, a cutoff
value for each recombinant fusion protein was established as
described in “Materials and Methods”, using the highest
b a c k g round value observed for each protein in the larg e
g roup of CMV- s e ronegative human sera. Figure 2 shows that
c u t o ffs, which in most cases re p resented a cluster of several
sera, were lower for LP than PP proteins because of a lower
overall background reactivity with LP proteins. The pro p o r-
tion of ELISA readings above the cutoff ranged from 8% to
44% for diff e rent LP proteins (ORF55, 33%; ORF45, 25%;
ORF94, 44%; ORF59, 8%; ORF154, 22%; and ORF152,
11%), with ORF55 and ORF94 exhibiting the highest per-
centage as well as the most significant diff e rence f rom con-
t rols as determined by the Mann-Whitney test (P = < . 0 0 0 1
and P = .02, respectively) (Figure 2). Although this statistical
evaluation is difficult to apply in settings where only a small
p e rcentage of individuals respond, such responses to antigens
can certainly be re p roducible and informative [18]. 
The authors believe that the small diff e rences in the
distribution observed with other LP proteins was attribut-
able to the very small numbers of CMV seropositive sera
that recognize these antigens, and supports the use of the
c u t o ff as an operational measure of specific i t y. The pro p o r-
tion of ELISA readings above the cutoff ranged from 11%
to 78% for diff e rent PP proteins (IE1, 25%; UL44, 47%;
UL57, 11%; UL83, 19%; UL80A, 36%; and UL32, 78%),
which was as expected from previous work [13]. Four of the
PP proteins, but only 2 of the LP proteins, exhibited
s i g n i ficant diff e rences when reactivity with CMV- s e ro p o s i-
tive sera was compared with control sera by use of the
Mann-Whitney test. As further evidence that re a c t i v i t y
above the cutoff was specific, sentinel samples of sera that
exhibited reactivity with a particular LP protein were sub-
jected to adsorption with either the GST or GST- L P
fusion protein for 1 hour at 4oC. In every sample tested,
ELISA reactivity toward an LP protein was removed by the
homologous antigen but not by GST alone (data not
shown). This supports the conclusion that responses to
some latent antigens were stronger than responses to oth-
ers, but that a subpopulation of infected individuals mount
a humoral response to each of the LP proteins. 
Comparison of Reactivity of Sera From Long-Term
Seropositive Individuals (Igg+/Igm–) With Sera From
Individuals Undergoing Active or Recent Infection
( I g G + / I g M + )
Individual LP proteins were recognized by at least 8%,
but no more than 44%, of serum samples from long-term
s e ropositive individuals (IgG+/IgM– by conventional
enzyme immunoassay) (Figures 2 and 3). Products of sense
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t r a nscripts (ORF94, ORF55, and ORF45) were recognized
by the highest percentage of sera (44%, 31%, and 25%,
respectively), whereas products of antisense transcripts
(ORF154, ORF152, and ORF59) were recognized by fewer
CMV-seropositive individuals (25%, 11%, and 8%, respec-
tively). The level and breadth of reactivity to these antigens
was reminiscent of responses to nonstructural proteins IE1,
ppUL57, and ppUL54 [17,18] (Figure 2), but was not as
s t rong as occurred with highly immunogenic antigens
ppUL44, ppUL83, and ppUL80A or the broadly recognized
antigen ppUL32 (Figure 2). A total of 85% of the sera from
CMV-seropositive individuals recognized at least 1 LP pro-
tein, but none recognized the entire set of 6 (data not
shown). In contrast to LP proteins, but as expected fro m
previous analyses [13,14,17,20,23,24,32], a larger percentage
of long-term seropositive individuals had antibody responses
to PP proteins ppUL32, ppUL44, and ppUL80a, with a
total of 97% of serum samples detecting at least 1 PP pro-
tein; 1 sample recognized all 6 proteins (data not shown).
Using the cutoff approach for each of the antigens, the
s e rologic responses to predicted LP proteins was found to
be less prevalent in individuals experiencing a recent active
CMV infection (IgG+/IgM+) than in long-term sero p o s i-
tive individuals (Figure 3). Within the group of CMV
IgG+/IgM+ samples, IgG responses to ORF94 and ORF45
w e re the most dramatically reduced (8% and 5%, re s p e c-
tively) when compared with the group of IgG+/IgM- sam-
ples (44% and 25%, respectively). As was the case for
IgG+/IgM– sera, ORF55 exhibited a high prevalence as well
as the most significant diff e rence in IgG+/IgM– samples
when compared with controls when analyzed by the Mann-
Whitney test (P = <.0001), and 2 other proteins exhibited a
clear significant diff e rence by this rank test (ORF45, 0.01;
ORF154, 0.002). Only about 50% of the IgG+/IgM+ serum
samples detected any 1 LP protein, and none recognized all
6 proteins (data not shown), suggesting that antibody to LP
proteins was slow to develop following active viral infection.
The sera that was reactive with LP proteins did not contain
any detectable LP protein-specific IgM, whereas PP pro-
teins were recognized by specific IgM as well as IgG in
many sera (data not shown). 
Overall, the serologic response to LP proteins in indi-
viduals with acute CMV infection appears to be low. Consis-
tent with previously published data [13], the sero l o g i c
response to PP proteins was variable (Figure 3). As expected
[23,24], reactivity to ppUL44 was widespread (80%), and
the percentage of sera reacting with ppUL57 and ppUL83
was also more prevalent among IgG+/IgM+ samples (33%
Figure 2. Antibody responsive to LP and PP fusion proteins. Each antigen was assayed for IgG responses against sera from 46 seronegative (the first group in the
subheading Human Sera Samples in “Materials and Methods”) and 36 seropositive (second group) individuals as determined by conventional enzyme immunoas-
say and immunoblot assay and described in “Materials and Methods.” The cutoff values (dashed lines) were set above the highest OD450 values obtained with
CMV-negative serum samples. The nonparametric Mann-Whitney test was used to compare the ranks of the seronegative and seropositive data, with the resulting
P value indicated above the scatter plot. The dotted line represents the limit of detection of the assay.
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and 36%, respectively) as opposed to IgG+/IgM– samples
(11% and 19%, respectively). A total of 97% of serum sam-
ples detected at least 1 PP protein and 2 sera recognized all
6 PP proteins (data not shown). These results suggest that
the immune response to LP antigens develops very slowly
following active infection, a possible result of low or delayed
expression relative to PP antigens.
Reactivity With Sera From Vir o l og i c a l l y Confirmed
P r i m a r y and Secondary Inf e c t i o n
To further investigate the level of serologic response to
individual LP proteins, reactivity to LP and PP proteins was
followed in sera of individuals undergoing virologically con-
firmed primary and secondary CMV infections. One gro u p
consisted of 185 sera from 29 immunocompetent and 13
i m m u n o c o m p romised individuals undergoing a confirm e d
p r i m a ry infection, and the other group consisted of 149 sam-
ples from 7 immunocompetent and 12 immunocompro m i s e d
individuals undergoing secondary infection. Less than 10% of
sera from immunocompetent individuals with ongoing pri-
m a ry CMV infection recognized any of the LP proteins, even
when these individuals were followed for 1 to 3 months after
infection (data not shown). Consistent with their sero c o n v e r-
sion by conventional enzyme immunoassay, 80% eventually
developed antibody to 1 or more PP protein (Figure 4).
When CMV- s e ronegative individuals who had received a
h e a rt or kidney from a CMV- s e ropositive donor were fol-
lowed for 2 years, all patients experienced CMV infection and
all sero c o n v e rted to 1 or more PP proteins within the first 9
months (mean, 3.5 months; range, 1-9 months after trans-
plant). In contrast, seroconversion to LP proteins was delayed
and appeared in only 7 patients (58%) after a very long inter-
val (mean, 12 months; range, 2-26 months after transplant).
In 5 of these cases, antibody to LP proteins was first detected
m o re than 10 months after active virus infection (assessed by
antigenemia assay or virus culture) and seroconversion to PP
p roteins occurred months earlier, suggesting that the sero-
conversion to LP proteins might not have been linked to the
levels of viral replication, as was seroconversion to PP pro-
teins. Following primary infection, the antibody levels to LP
p roteins among those who sero c o n v e rted reached 2 to 6.5
times the cutoff values in a large majority of individuals, with
the highest antibody titers observed to ORF59 and ORF154
(data not shown). The LP products reacted with a smaller
p e rcentage of sera (from a low of 1% for ORF55 to a high of
14% for ORF45; Figure 4) than PP products (from a low of
7% for IE1 to a high of 83% for ppUL44; Figure 4), and
none of these serum samples reacted with all 6 LP or all 6 PP
p roteins (data not shown).
Following a secondary infection, ORF59 was the most
widely recognized LP protein (48% of sera), followed by
ORF55 and ORF154 (37% and 25% of sera, respectively);
Figure 3. Percentage of serum recognizing LP and PP fusion proteins in long-term seropositive individuals and in individuals with acute or recent infection. There
were 36 serum samples from long-term seropositive individuals (IgG+/IgM–, second group under Human Sera Samples in “Materials and Methods”) and 39
serum samples from individuals with acute or recent infection (IgG+/IgM+, third group) that were assayed by ELISA for reactivity with LP and PP fusion proteins.
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h o w e v e r, none of the serum samples reacted with all LP
proteins (data not shown). The antibody levels among sero-
converters to LP proteins varied from 2 to 13 times the cut-
o ff, with the highest being observed against ORF59 and
ORF154 (data not shown). As expected, the broadest reac-
tivity to PP proteins was to ppUL32 (96% of sera), followed
by ppUL80a (70% of sera) and ppUL44 (63% of sera); how-
ever, none of the serum samples reacted with all 6 PP pro-
teins (data not shown).
P r esence of Antibody to Predicted LP Proteins in
C o m m e r cial Gamma Globulin Pr e p a r a t i o n s
In 2 cases of primary infection in transplant recipients,
the presence of IgG to LP and PP proteins was detected
immediately following transplantation and before any sign
of CMV infection. Clinical re c o rds indicated that both
patients had been treated with anti-CMV hyperimmune
gamma globulins that have measurable levels of antibody to
PP proteins. To determine whether commercially available
IgG preparations contained antibodies to LP proteins, 2 dif-
f e rent preparations (Cytotek from Biotest, Marburg, Ger-
many, and Endobulin, from Immuno AG, Vienna, Austria)
w e re evaluated. Both preparations showed reactivity to at
least 1 LP protein. One in particular (Biotest), which was
described as hyperimmune for CMV by the manufacture r,
showed the presence of antibodies to all 3 predicted LP pro-
teins (ORF45, ORF94, and ORF55) encoded by sense tran-
scripts and 1 protein (ORF154) from antisense transcripts,
as well as antibodies to 4 (ppUL44, UL57, ppUL83, and
ppUL32) of 6 PP proteins (data not shown). The nature of
the sera used to produce this batch of gamma globulin is not
known, but it is expected that long-term seropositive indi-
viduals predominated in the proportion of donors who were
s e ropositive. Thus, commercial preparations of gamma
globulins used for immunoprophylaxis of CMV contain
antibodies to both LP and PP proteins.
DISCUSSION
This study analyzed the level of the humoral immune
response to 6 proteins, made in bacteria as GST-fusion pro-
teins, predicted to be encoded by latency-associated ORFs, 3
f rom sense (ORF55, ORF45, and ORF94) and 3 from anti-
sense (ORF59, ORF154, and ORF152) transcripts. The
results indicate that specific antibody to all 6 LP proteins is
induced in a subset of individuals infected with CMV, indi-
cating that all of these proteins are expressed during natural
infection. Seroconversion to LP proteins was delayed follow-
ing the resolution of active CMV infection in immunocom-
p romised individuals. Direct detection of PP antigens by
antigenemia or viral DNA by PCR are effective means to
identify active CMV infection [33], and serologic assays for
PP antigens provide a useful way to identify long-term ,
latently infected individuals in the population. Sero l o g i c
responses to latency-associated proteins do not appear to rise
within a time frame that would be useful in any clinical set-
ting. The response to these proteins appeared more variable
in both strength and breadth than the response to PP
Figure 4. Percentage of individuals undergoing primary and secondary CMV infection whose serum show reactivity to LP and PP fusion proteins. There were
85 sera from 29 immunocompetent and 13 immunocompromised subjects undergoing primary CMV infection (fourth group under Human Sera Samples in
“Materials and Methods”), and 149 samples from 7 immunocompetent adults and 12 immunocompromised individuals undergoing a secondary CMV infection
(fifth group) that were assayed by ELISA for reactivity with LP and PP fusion proteins. A patient was considered seropositive to a particular LP or PP if any of
multiple serum samples obtained from that individual recognized the antigen above the cutoff. These results represent the percentage of patients with antigen-spe-
cific antibody.
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p roteins chosen for comparison in healthy seropositive indi-
viduals as well as in individuals who had undergone active
CMV infections. ORF55 and ORF154 induced the stro n g e s t
antibody response of LP proteins, and ORF55 and ORF94
induced a response in the greatest number of individuals. In
t e rms of breadth and level of response, LP proteins induced
a response that was most similar to PP proteins IE1,
ppUL57, and ppUL83 rather than more highly immuno-
genic PP proteins. As was the case for weakly immunogenic
PP proteins, the breadth of responses to individual LP pro-
teins appears to be too limited to consider these antigens as
markers to identify latently infected individuals, although the
fact that 85% of sera reacted to any 1 protein suggests that
they should be evaluated as a group. The presence of a sero-
logic response to LP proteins does not appear to be pre d i c-
tive of viral reactivation or disease, and screening for this
response in donors would not likely provide any benefit .
The percentage of individuals with antibodies to any 1 L P
p rotein varied from a minimum of 5% to a maximum of 48%,
and only an IgG response was detected. As observed here for
LP proteins, previous evaluation of the PP protein ppUL54
(viral DNA polymerase) [18] had revealed an IgG response in
the absence of an IgM response. When the total number
(409) of CMV- s e ropositive sera tested are considered, most of
the LP protein-positive samples also recognized at least 1 PP
p rotein (146 of 409), although a significant number of PP
p rotein-positive sera did not recognize any of the LP pro t e i n s
(199 of 409), and many failed to recognize any of the 12 re c o m-
binant CMV proteins at all (58 of 409). Ve ry few sera failed to
recognize PP proteins and yet recognized 1 of the LP pro-
teins (6 of 409). Thus, sera that recognize LP proteins also
typically contain antibody to PP pro t e i n s .
On follow-up examination, transplant recipients were
found to develop antibodies to LP protein with a signifi-
cantly delayed time course relative to PP proteins. There
was not sufficient data to undertake a similar evaluation in
immunocompetent subjects because they were not followed
for a sufficient period of time. However, the delayed anti-
body response may not be unique to LP proteins. Schoppel
et al. [32] described a 2- to 4-month delay in the develop-
ment of antibody to CMV envelope glycoproteins re l a t i v e
to some of the same PP proteins used in the current study
following primary infection in immunocompromised and
immunocompetent individuals. The delay that was observed
in responses to LP proteins was more pronounced than that
reported to occur with envelope glycoproteins. Direct com-
parisons are complicated by the fact that the response to any
PP glycoproteins was not investigated in the current study.
The significant delay in detecting an LP pro t e i n - s p e c i f i c
immune response is consistent with their expression during
p rolonged latency rather than during productive infection;
h o w e v e r, this may also have resulted from lower levels of
expression or a reduced immunogenicity of this class of pro-
teins relative to PP proteins. It is also possible that individu-
als who develop antibodies to LP proteins over a prolonged
2-year period may also have experienced additional unde-
tected CMV infections that boosted their response. The
detection of a greater percentage of sera with reactivity for
LP proteins in individuals who had experienced a secondary
infection supports the suggestion that a booster effect can
occur.
In conclusion, this work establishes the presence of
antibody to LP proteins in  both healthy long-term
s e ropositive individuals as well as in some individuals
u n d e rgoing active or recent infection. These results sup-
p o rt the detection of transcripts from this region of the
CMV genome in a large fraction of the population [8], and
a re consistent with the detection of these protein expre s-
sions during natural infection. 
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